[Experience in long-term use of berodual in the treatment of patients with chronic obstructive bronchitis]. / Opyt dlitel'nogo primeneniia beroduala pri lechenii bol'nykh khronicheskim obstruktivnym bronkhitom.

AIM: To study clinical efficiency of 12-month administration of berodual in chronic obstructive bronchitis (COB). MATERIALS AND METHODS: The trial entered 33 patients with at least 2-year history of COB and forced expiratory volume per 1 sec (FEV1) not less than 45% of normal value. RESULTS: The best response of clinical parameters and external respiration was observed throughout 3 weeks of berodual inhalations. Dyspnea and cough were cured by the end of the treatment in 40 and 26% of the patients, respectively. Exercise tolerance has improved, FEV1 has increased for the year from 71.9 to 79.1%. CONCLUSION: Long-term berodual monotherapy is able to inhibit progression of bronchial obstruction and symptoms of COB.

[Comparative study of the effectiveness of equivalent doses of the preparation ditek, disodium cromoglycate and fenoterol in atopic bronchial asthma]. / Sravnitel'naia éffektivnost' ékvivalentnykh doz preparata "Ditek", dinatrievogo khromoglikata i fenoterola pri atopicheskoi bronkhial'noi astme.

18-45-year-old patients with atopic bronchial asthma free of associated inflammatory diseases received ditek, lomudal and berotek (28, 10 and 10 patients, respectively). Biochemical assessment of allergic inflammation activity demonstrated that ditek is most effective of the above three drugs both in relation to induction of clinical remission and to inhibition of allergic inflammation.